GlassScriptPhysician profile
Vitaliy Koss
NPI 1205149424
$187,637.89
in general payments reported to CMS, 2019-2025
11 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $43K · 2021: $57K · 2022: $26K · 2023: $5,907 · 2024: $5,940 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Honoraria: $6,613 · Food and Beverage: $2,010 · Consulting Fee: $1,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,968.75 |
| Honoraria | $6,613.00 |
| Food and Beverage | $2,010.36 |
| Consulting Fee | $1,750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $51,943.30 | 2019-2022 | |
| Abbvie INC. | $40,050.99 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $27,116.47 | 2019-2024 | Austedo Xr |
| Allergan, INC. | $25,960.81 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $17,709.35 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15,018.43 | 2022 | |
| Axsome Therapeutics, INC. | $6,737.74 | 2025 | Symbravo |
| Pfizer INC. | $1,750.00 | 2025 | |
| Lundbeck LLC | $1,126.14 | 2020-2025 | Vyepti |
| Promius Pharma LLC | $124.80 | 2019 | |
| Impel Pharmaceuticals INC. | $99.86 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vitaliy Koss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.